120 related articles for article (PubMed ID: 25044638)
1. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
Wang S; Cao M; Deng X; Xiao X; Yin Z; Hu Q; Zhou Z; Zhang F; Zhang R; Wu Y; Sheng W; Zeng Y
Adv Healthc Mater; 2015 Jan; 4(2):281-90. PubMed ID: 25044638
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer.
Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y
Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
[TBL] [Abstract][Full Text] [Related]
4. Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model.
Hu QL; Jiang QY; Jin X; Shen J; Wang K; Li YB; Xu FJ; Tang GP; Li ZH
Biomaterials; 2013 Mar; 34(9):2265-76. PubMed ID: 23298779
[TBL] [Abstract][Full Text] [Related]
5. Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells.
Parmar MB; Meenakshi Sundaram DN; K C RB; Maranchuk R; Montazeri Aliabadi H; Hugh JC; Löbenberg R; Uludağ H
Acta Biomater; 2018 Jan; 66():294-309. PubMed ID: 29183848
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Targeting Anti-MicroRNA-155 Delivery Based on Biodegradable Poly(ester amine) and Hyaluronic Acid Shielding for Lung Cancer Therapy.
Yang Y; Jia Y; Xiao Y; Hao Y; Zhang L; Chen X; He J; Zhao Y; Qian Z
Chemphyschem; 2018 Aug; 19(16):2058-2069. PubMed ID: 29488305
[TBL] [Abstract][Full Text] [Related]
7. Consecutive targetable smart nanoprobe for molecular recognition of cytoplasmic microRNA in metastatic breast cancer.
Kim E; Yang J; Park J; Kim S; Kim NH; Yook JI; Suh JS; Haam S; Huh YM
ACS Nano; 2012 Oct; 6(10):8525-35. PubMed ID: 22947044
[TBL] [Abstract][Full Text] [Related]
8. In vivo visualization of endogenous miR-21 using hyaluronic acid-coated graphene oxide for targeted cancer therapy.
Hwang DW; Kim HY; Li F; Park JY; Kim D; Park JH; Han HS; Byun JW; Lee YS; Jeong JM; Char K; Lee DS
Biomaterials; 2017 Mar; 121():144-154. PubMed ID: 28088076
[TBL] [Abstract][Full Text] [Related]
9. Nanovesicle-mediated systemic delivery of microRNA-34a for CD44 overexpressing gastric cancer stem cell therapy.
Jang E; Kim E; Son HY; Lim EK; Lee H; Choi Y; Park K; Han S; Suh JS; Huh YM; Haam S
Biomaterials; 2016 Oct; 105():12-24. PubMed ID: 27497057
[TBL] [Abstract][Full Text] [Related]
10. Superiority of aromatase inhibitor and cyclooxygenase-2 inhibitor combined delivery: Hyaluronate-targeted versus PEGylated protamine nanocapsules for breast cancer therapy.
Elzoghby AO; Mostafa SK; Helmy MW; ElDemellawy MA; Sheweita SA
Int J Pharm; 2017 Aug; 529(1-2):178-192. PubMed ID: 28663087
[TBL] [Abstract][Full Text] [Related]
11. Versatile protamine nanocapsules to restore miR-145 levels and interfere tumor growth in colorectal cancer cells.
Reimondez-Troitiño S; González-Aramundiz JV; Ruiz-Bañobre J; López-López R; Alonso MJ; Csaba N; de la Fuente M
Eur J Pharm Biopharm; 2019 Sep; 142():449-459. PubMed ID: 31326581
[TBL] [Abstract][Full Text] [Related]
12. CD44 targeting hyaluronic acid coated lapatinib nanocrystals foster the efficacy against triple-negative breast cancer.
Agrawal S; Dwivedi M; Ahmad H; Chadchan SB; Arya A; Sikandar R; Kaushik S; Mitra K; Jha RK; Dwivedi AK
Nanomedicine; 2018 Feb; 14(2):327-337. PubMed ID: 29129754
[TBL] [Abstract][Full Text] [Related]
13. Delivery of dual miRNA through CD44-targeted mesoporous silica nanoparticles for enhanced and effective triple-negative breast cancer therapy.
Ahir M; Upadhyay P; Ghosh A; Sarker S; Bhattacharya S; Gupta P; Ghosh S; Chattopadhyay S; Adhikary A
Biomater Sci; 2020 May; 8(10):2939-2954. PubMed ID: 32319481
[TBL] [Abstract][Full Text] [Related]
14. Cationic microRNA-delivering nanocarriers for efficient treatment of colon carcinoma in xenograft model.
Liang G; Zhu Y; Jing A; Wang J; Hu F; Feng W; Xiao Z; Chen B
Gene Ther; 2016 Dec; 23(12):829-838. PubMed ID: 27482839
[TBL] [Abstract][Full Text] [Related]
15. Polymer-Initiating Caveolae-Mediated Endocytosis and GSH-Responsive MiR-34a Gene Delivery System for Enhanced Orthotopic Triple Negative Breast Cancer Therapy.
Han TY; Huan ML; Cai Z; He W; Zhou SY; Zhang BL
Adv Healthc Mater; 2023 Dec; 12(32):e2302094. PubMed ID: 37827986
[TBL] [Abstract][Full Text] [Related]
16. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
Adams BD; Wali VB; Cheng CJ; Inukai S; Booth CJ; Agarwal S; Rimm DL; Győrffy B; Santarpia L; Pusztai L; Saltzman WM; Slack FJ
Cancer Res; 2016 Feb; 76(4):927-39. PubMed ID: 26676753
[TBL] [Abstract][Full Text] [Related]
17. Protamine sulfate-nanodiamond hybrid nanoparticles as a vector for MiR-203 restoration in esophageal carcinoma cells.
Cao M; Deng X; Su S; Zhang F; Xiao X; Hu Q; Fu Y; Yang BB; Wu Y; Sheng W; Zeng Y
Nanoscale; 2013 Dec; 5(24):12120-5. PubMed ID: 24154605
[TBL] [Abstract][Full Text] [Related]
18. TRAIL-induced miR-146a expression suppresses CXCR4-mediated human breast cancer migration.
Wang D; Liu D; Gao J; Liu M; Liu S; Jiang M; Liu Y; Zheng D
FEBS J; 2013 Jul; 280(14):3340-53. PubMed ID: 23647548
[TBL] [Abstract][Full Text] [Related]
19. Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy.
Jing H; Cheng W; Li S; Wu B; Leng X; Xu S; Tian J
Colloids Surf B Biointerfaces; 2016 Oct; 146():387-95. PubMed ID: 27388967
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1.
Yang S; Li Y; Gao J; Zhang T; Li S; Luo A; Chen H; Ding F; Wang X; Liu Z
Oncogene; 2013 Sep; 32(36):4294-303. PubMed ID: 23001043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
